Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
| Fiscal year / year | SIGA Technologies revenue |
|---|---|
| 2009 | $13.8M |
| 2010 | $19.2M |
| 2011 | $12.7M |
| 2012 | $9.0M |
| 2013 | $5.5M |
| 2014 | $3.1M |
| 2015 | $8.2M |
| 2016 | $15.0M |
| 2017 | $12.3M |
| 2018 | $477.1M |
| 2019 | $26.7M |
| 2020 | $115.5M |
Rate SIGA Technologies' financial transparency
SIGA Technologies saw the greatest revenue growth in 2018, when revenue increased by 3,788.3%.
SIGA Technologies had the lowest revenue growth in 2019, when revenue changed by -94.39%.
| Year | SIGA Technologies growth |
|---|---|
| 2009 | 71%↑ |
| 2010 | 39%↑ |
| 2011 | -34%↓ |
| 2012 | -30%↓ |
| 2013 | -38%↓ |
| 2014 | -43%↓ |
| 2015 | 160%↑ |
| 2016 | 83%↑ |
| 2017 | -18%↓ |
| 2018 | 3788%↑ |
| 2019 | -94%↓ |
| 2020 | 332%↑ |
Do you work at SIGA Technologies?
Is SIGA Technologies transparent about its revenue structure?
| CEO | Phillip Louis Gomez III |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 43 |
| Date Founded | 1995 |
| Headquarters | New York, New York |
| Revenue | $115.5M |
| Net Income | $33,904,806 |
| Gross Proft | $100.7M (2020) |
| PE Ratio | 9.97 |
| Tax Rate | 0.2% |
| Market Capitalization | $561.5M |
| Total Assets | $195,035,923 |
| Ticker | SIGA |
SIGA Technologies received early financing of $3.0M on 2000-04-10.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $3M | 04/2000 |
| Grant | $55M | 09/2008 |
| Grant | $3M | 09/2009 |
| Grant | $23M | 06/2020 |
| Investors | Security type |
|---|---|
| National Institutes of Health (NIH) | Grant |
| Biomedical Advanced Research and Development Authority (BARDA) | Grant |
| National Institute of Allergy and Infectious Diseases (NIAID) | Grant |
| National Institutes of Health (NIH) | Grant |
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Merck | $90,328 | $64.2B | 74,000 | 2,272 |
| Esperion Therapeutics | $75,747 | $332.3M | 218 | 32 |
| Salix Pharmaceuticals | $106,558 | $1.1B | 1,000 | - |
| Neurocrine Biosciences | $78,232 | $2.4B | 400 | 386 |
| Fortress Biotech | $51,379 | $84.5M | 34 | - |
| bluebird bio | $98,505 | $3.7M | 518 | 10 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 692 |
| Amgen | $93,349 | $33.4B | 22,000 | 633 |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Sutro Biopharma | $89,543 | $62.0M | 160 | 8 |
Zippia gives an in-depth look into the details of SIGA Technologies, including salaries, political affiliations, employee data, and more, in order to inform job seekers about SIGA Technologies. The employee data is based on information from people who have self-reported their past or current employments at SIGA Technologies. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by SIGA Technologies. The data presented on this page does not represent the view of SIGA Technologies and its employees or that of Zippia.
SIGA Technologies may also be known as or be related to SIGA TECHNOLOGIES INC, SIGA Technologies, SIGA Technologies, Inc., Siga Technologies and Siga Technologies, Inc.